NCT02880956 is a Phase 2 clinical trial of ABBV-8E12 in Alzheimer's Disease, sponsored by AbbVie.

Who is sponsoring NCT02880956?

NCT02880956 is sponsored by AbbVie.

What drugs are being tested in NCT02880956?

Interventions in NCT02880956: ABBV-8E12, placebo for ABBV-8E12.

What condition does NCT02880956 study?

NCT02880956 studies Alzheimer's Disease.

Is NCT02880956 still recruiting?

NCT02880956 is currently completed. Last updated 26 August 2022.

Are results published for NCT02880956?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-08-26 · How we verify

NCT02880956

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

Completed Phase 2 Results posted Last updated 26 August 2022

What this trial tests

Phase 2 trial testing ABBV-8E12 in Alzheimer's Disease in 453 participants. Completed in 28 July 2021.

Timeline

26 January 2017

Primary endpoint
30 March 2021

28 July 2021

Quick facts

Lead sponsor	AbbVie
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	453
Start date	26 January 2017
Primary completion	30 March 2021
Estimated completion	28 July 2021
Sites	68 locations across Denmark, Italy, Finland, Netherlands, New Zealand, Belgium, Sweden, Canada

Drugs / interventions tested

ABBV-8E12 — full drug profile →
placebo for ABBV-8E12 — full drug profile →

Conditions studied

Alzheimer's Disease — all drugs for Alzheimer's Disease →

Sponsor

AbbVie — full company profile →

Who can join

Adults 55 to 85, any sex, with Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change From Baseline Over Time in CDR-SB Score Primary · Baseline, Week 24, Week 48, Week 72, Week 96

The CDR-SB is a numeric scale used to quantify the severity of symptoms of dementia. A qualified health professional assesses a participant's cognitive and functional performance in 6 areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. The CDR scale gives a score from 0 to 3 for each of the 6 areas, with a lower value being desirable. The sum of these 6 areas, the CDR-SB score, can range from 0 to 18, with a lower value being desirable.

Change to Week 24

Group	Value	95% CI
Placebo	0.60	± 0.125
ABBV-8E12 300 mg	0.66	± 0.129
ABBV-8E12 1000 mg	0.44	± 0.125
ABBV-8E12 2000 mg	0.63	± 0.130

Change to Week 48

Group	Value	95% CI
Placebo	1.06	± 0.155
ABBV-8E12 300 mg	1.15	± 0.161
ABBV-8E12 1000 mg	1.05	± 0.154
ABBV-8E12 2000 mg	0.99	± 0.161

Change to Week 72

Group	Value	95% CI
Placebo	1.90	± 0.213
ABBV-8E12 300 mg	1.88	± 0.220
ABBV-8E12 1000 mg	1.85	± 0.212
ABBV-8E12 2000 mg	1.81	± 0.219

Change to Week 96

Group	Value	95% CI
Placebo	2.54	± 0.271
ABBV-8E12 300 mg	2.47	± 0.277
ABBV-8E12 1000 mg	2.48	± 0.267
ABBV-8E12 2000 mg	2.70	± 0.279

Number of Participants With Treatment Emergent Adverse Events (TEAEs) Primary · From first dose of study drug up to last dose of study drug plus 20 weeks (up to Week 112)

A TEAE was defined as an adverse event (AE) that began on or after the first study drug dose date and no more than 20 weeks after the last dose of study drug. An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. Serious AEs (SAEs) were defined as an event that results in death, is life-threatening, results in hospitalization or prolongs hospitalization, is a congenital abnormality, results in persistent or significant disability/incapacity, or is an important medical event. Events were rated in severity

Any TEAE

Group	Value	95% CI
Placebo	108
ABBV-8E12 300 mg	94
ABBV-8E12 1000 mg	108
ABBV-8E12 2000 mg	104

Severe TEAE

Group	Value	95% CI
Placebo	12
ABBV-8E12 300 mg	13
ABBV-8E12 1000 mg	14
ABBV-8E12 2000 mg	11

TEAE With a Reasonable Possibility to Study Drug

Group	Value	95% CI
Placebo	28
ABBV-8E12 300 mg	32
ABBV-8E12 1000 mg	31
ABBV-8E12 2000 mg	33

SAE

Group	Value	95% CI
Placebo	26
ABBV-8E12 300 mg	19
ABBV-8E12 1000 mg	22
ABBV-8E12 2000 mg	17

TEAE Leading to Discontinuation of Study Drug

Group	Value	95% CI
Placebo	4
ABBV-8E12 300 mg	6
ABBV-8E12 1000 mg	6
ABBV-8E12 2000 mg	4

Fatal TEAE

Group	Value	95% CI
Placebo	1
ABBV-8E12 300 mg	2
ABBV-8E12 1000 mg	2
ABBV-8E12 2000 mg	1

All Deaths

Group	Value	95% CI
Placebo	1
ABBV-8E12 300 mg	2
ABBV-8E12 1000 mg	2
ABBV-8E12 2000 mg	1

Maximum Observed Serum Concentration (Cmax) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses Secondary · Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.

First Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	108	± 28
ABBV-8E12 1000 mg	284	± 21
ABBV-8E12 2000 mg	528	± 27

Fourth Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	168	± 23
ABBV-8E12 1000 mg	426	± 20
ABBV-8E12 2000 mg	806	± 37

Time to Cmax (Tmax) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses Secondary · Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.

First Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	3	1.8 – 4.2
ABBV-8E12 1000 mg	2.5	1.3 – 4.2
ABBV-8E12 2000 mg	2.7	1.7 – 3.6

Fourth Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	2.4	1.1 – 4.1
ABBV-8E12 1000 mg	2.5	1.7 – 4.3
ABBV-8E12 2000 mg	2.3	1.7 – 3.6

Serum Concentration at the End of a Dose Interval (Ctrough) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses Secondary · Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.

First Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	28.6	± 22
ABBV-8E12 1000 mg	75.1	± 33
ABBV-8E12 2000 mg	163	± 26

Fourth Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	56.4	± 25
ABBV-8E12 1000 mg	182	± 29
ABBV-8E12 2000 mg	320	± 36

Half-Life (T1/2) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses Secondary · Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.

Harmonic mean is presented in the data table.

First Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	22.0	± 17.2
ABBV-8E12 1000 mg	19.4	± 8.87
ABBV-8E12 2000 mg	33.2	± 10.5

Fourth Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	19.6	± 6.09
ABBV-8E12 1000 mg	24.0	± 16.6
ABBV-8E12 2000 mg	37.5	± 13.5

Area Under the Concentration-Time Curve From Dosing (Time 0) to Day 28 (AUC0-28) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses Secondary · Day 1 (Dose 1): pre-infusion, up to Day 29 (trough level before Dose 2). Day 85 (Dose 4): pre-infusion, up to Day 113 (trough level before Dose 5). See Outcome Measure description above for complete time point details.

* The AUC0-28 for Dose 1 included the following timepoints: pre-infusion, post-infusion (within 15 min), 1 and 2 hours post-infusion, Day 5, Day 15 and Day 29 (trough level before Dose 2). * The AUC0-28 for Dose 4 included the following timepoints: Day 85 pre-infusion, post-infusion (within 15 min), 1 and 2 hours post-infusion, Day 89, Day 99 and Day 113 (trough level before Dose 5).

First Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	2520	± 28
ABBV-8E12 1000 mg	6090	± 37
ABBV-8E12 2000 mg	14800	± 25

Fourth Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	4230	± 33
ABBV-8E12 1000 mg	13100	± 36
ABBV-8E12 2000 mg	30200	± 36

Cmax/Dose for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses Secondary · Day 1 (Dose 1): Pre-infusion, post-infusion (within 15 minutes), 1 and 2 hours post-infusion; Days 5 and 15. Day 85 (Dose 4): Pre-infusion (0 hour), post-infusion (within 15 minutes) and 1 and 2 hours post-infusion; Days 89 and 99.

First Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	0.359	± 28
ABBV-8E12 1000 mg	0.284	± 21
ABBV-8E12 2000 mg	0.264	± 27

Fourth Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	0.561	± 23
ABBV-8E12 1000 mg	0.426	± 20
ABBV-8E12 2000 mg	0.403	± 37

AUC0-28/Dose for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses Secondary · Day 1 (Dose 1): pre-infusion, up to Day 29 (trough level before Dose 2). Day 85 (Dose 4): pre-infusion, up to Day 113 (trough level before Dose 5). See Outcome Measure description above for complete time point details.

* The AUC0-28/dose for Dose 1 included the following timepoints: pre-infusion, post-infusion (within 15 min), 1 and 2 hours post-infusion, Day 5, Day 15 and Day 29 (trough level before Dose 2). * The AUC0-28/dose for Dose 4 included the following timepoints: Day 85 pre-infusion, post-infusion (within 15 min), 1 and 2 hours post-infusion, Day 89, Day 99 and Day 113 (trough level before Dose 5).

First Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	8.40	± 28
ABBV-8E12 1000 mg	6.09	± 37
ABBV-8E12 2000 mg	7.41	± 25

Fourth Dosing Interval

Group	Value	95% CI
ABBV-8E12 300 mg	14.1	± 33
ABBV-8E12 1000 mg	13.1	± 36
ABBV-8E12 2000 mg	15.1	± 36

Change From Baseline Over Time in Alzheimer's Disease Assessment Scale (14-Item) Cognition Portion (ADAS-Cog-14) Total Score Secondary · Baseline, Week 24, Week 48, Week 72, Week 96

The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 \[1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task\] and includes 3 additional tasks \[12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning\], for increa

Change at Week 24

Group	Value	95% CI
Placebo	1.82	± 0.492
ABBV-8E12 300 mg	1.42	± 0.498
ABBV-8E12 1000 mg	0.56	± 0.480
ABBV-8E12 2000 mg	1.86	± 0.503

Change at Week 48

Group	Value	95% CI
Placebo	4.50	± 0.621
ABBV-8E12 300 mg	3.51	± 0.642
ABBV-8E12 1000 mg	3.42	± 0.605
ABBV-8E12 2000 mg	4.03	± 0.647

Change at Week 72

Group	Value	95% CI
Placebo	5.26	± 0.718
ABBV-8E12 300 mg	4.78	± 0.730
ABBV-8E12 1000 mg	5.00	± 0.706
ABBV-8E12 2000 mg	6.37	± 0.738

Change at Week 96

Group	Value	95% CI
Placebo	8.43	± 0.898
ABBV-8E12 300 mg	7.99	± 0.891
ABBV-8E12 1000 mg	7.84	± 0.872
ABBV-8E12 2000 mg	9.46	± 0.935

Change From Baseline Over Time in ADAS-Cog-14 Comprehension of Spoken Language Score Secondary · Baseline, Week 24, Week 48, Week 72, Week 96

Change at Week 24

Group	Value	95% CI
Placebo	0.01	± 0.038
ABBV-8E12 300 mg	0.03	± 0.038
ABBV-8E12 1000 mg	0.04	± 0.037
ABBV-8E12 2000 mg	0.08	± 0.039

Change at Week 48

Group	Value	95% CI
Placebo	0.03	± 0.044
ABBV-8E12 300 mg	0.09	± 0.046
ABBV-8E12 1000 mg	0.07	± 0.044
ABBV-8E12 2000 mg	0.12	± 0.046

Change at Week 72

Group	Value	95% CI
Placebo	0.17	± 0.064
ABBV-8E12 300 mg	0.11	± 0.066
ABBV-8E12 1000 mg	0.14	± 0.064
ABBV-8E12 2000 mg	0.31	± 0.066

Change at Week 96

Group	Value	95% CI
Placebo	0.30	± 0.083
ABBV-8E12 300 mg	0.26	± 0.083
ABBV-8E12 1000 mg	0.19	± 0.080
ABBV-8E12 2000 mg	0.29	± 0.085

Change From Baseline Over Time in ADAS-Cog-14 Constructional Praxis Score Secondary · Baseline, Week 24, Week 48, Week 72, Week 96

Change at Week 24

Group	Value	95% CI
Placebo	0.11	± 0.057
ABBV-8E12 300 mg	0.05	± 0.058
ABBV-8E12 1000 mg	-0.02	± 0.056
ABBV-8E12 2000 mg	0.09	± 0.059

Change at Week 48

Group	Value	95% CI
Placebo	0.07	± 0.073
ABBV-8E12 300 mg	0.23	± 0.077
ABBV-8E12 1000 mg	0.17	± 0.072
ABBV-8E12 2000 mg	0.20	± 0.077

Change at Week 72

Group	Value	95% CI
Placebo	0.25	± 0.069
ABBV-8E12 300 mg	0.22	± 0.072
ABBV-8E12 1000 mg	0.16	± 0.070
ABBV-8E12 2000 mg	0.16	± 0.071

Change at Week 96

Group	Value	95% CI
Placebo	0.41	± 0.089
ABBV-8E12 300 mg	0.25	± 0.089
ABBV-8E12 1000 mg	0.026	± 0.086
ABBV-8E12 2000 mg	0.33	± 0.092

Adverse events — posted to ClinicalTrials.gov

Time frame: From the time of study drug administration until 20 weeks following discontinuation of study drug administration. Overall median time on study was 680.0 days.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo

Serious: 26/116 (22%)

Deaths: 1/116

ABBV-8E12 300 mg

Serious: 19/108 (18%)

Deaths: 2/108

ABBV-8E12 1000 mg

Serious: 22/116 (19%)

Deaths: 2/116

ABBV-8E12 2000 mg

Serious: 17/113 (15%)

Deaths: 1/113

Serious adverse events (95 terms)

Reaction	System	Placebo	ABBV-8E12 300 mg	ABBV-8E12 1000 mg	ABBV-8E12 2000 mg
URINARY TRACT INFECTION	Infections and infestations	—	—	—	—
FALL	Injury, poisoning and procedural complications	—	—	—	—
SYNCOPE	Nervous system disorders	—	—	—	—
MYOCARDIAL INFARCTION	Cardiac disorders	—	—	—	—
DIVERTICULITIS	Infections and infestations	—	—	—	—
PNEUMONIA	Infections and infestations	—	—	—	—
RIB FRACTURE	Injury, poisoning and procedural complications	—	—	—	—
HYPONATRAEMIA	Metabolism and nutrition disorders	—	—	—	—
OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	—	—	—	—
CEREBROVASCULAR ACCIDENT	Nervous system disorders	—	—	—	—
PULMONARY EMBOLISM	Respiratory, thoracic and mediastinal disorders	—	—	—	—
ARTERIOSCLEROSIS CORONARY ARTERY	Cardiac disorders	—	—	—	—
ATRIAL FIBRILLATION	Cardiac disorders	—	—	—	—
ATRIAL FLUTTER	Cardiac disorders	—	—	—	—
BRADYCARDIA	Cardiac disorders	—	—	—	—
MYOCARDITIS	Cardiac disorders	—	—	—	—
RIGHT VENTRICULAR FAILURE	Cardiac disorders	—	—	—	—
SINUS NODE DYSFUNCTION	Cardiac disorders	—	—	—	—
ABDOMINAL PAIN	Gastrointestinal disorders	—	—	—	—
CONSTIPATION	Gastrointestinal disorders	—	—	—	—
DYSPHAGIA	Gastrointestinal disorders	—	—	—	—
GASTRIC ULCER HAEMORRHAGE	Gastrointestinal disorders	—	—	—	—
GASTROINTESTINAL HAEMORRHAGE	Gastrointestinal disorders	—	—	—	—
NAUSEA	Gastrointestinal disorders	—	—	—	—
PANCREATITIS ACUTE	Gastrointestinal disorders	—	—	—	—

Other adverse events (26 terms — click to expand)

Reaction	System	Placebo	ABBV-8E12 300 mg	ABBV-8E12 1000 mg	ABBV-8E12 2000 mg
FALL	Injury, poisoning and procedural complications	—	—	—	—
HEADACHE	Nervous system disorders	—	—	—	—
UPPER RESPIRATORY TRACT INFECTION	Infections and infestations	—	—	—	—
ANXIETY	Psychiatric disorders	—	—	—	—
DIZZINESS	Nervous system disorders	—	—	—	—
URINARY TRACT INFECTION	Infections and infestations	—	—	—	—
DIARRHOEA	Gastrointestinal disorders	—	—	—	—
NASOPHARYNGITIS	Infections and infestations	—	—	—	—
ARTHRALGIA	Musculoskeletal and connective tissue disorders	—	—	—	—
DEPRESSION	Psychiatric disorders	—	—	—	—
VOMITING	Gastrointestinal disorders	—	—	—	—
FATIGUE	General disorders	—	—	—	—
BACK PAIN	Musculoskeletal and connective tissue disorders	—	—	—	—
NAUSEA	Gastrointestinal disorders	—	—	—	—
COUGH	Respiratory, thoracic and mediastinal disorders	—	—	—	—
SINUSITIS	Infections and infestations	—	—	—	—
CONTUSION	Injury, poisoning and procedural complications	—	—	—	—
SKIN ABRASION	Injury, poisoning and procedural complications	—	—	—	—
SKIN LACERATION	Injury, poisoning and procedural complications	—	—	—	—
INSOMNIA	Psychiatric disorders	—	—	—	—
SEASONAL ALLERGY	Immune system disorders	—	—	—	—
BRONCHITIS	Infections and infestations	—	—	—	—
INFLUENZA	Infections and infestations	—	—	—	—
MUSCULOSKELETAL CHEST PAIN	Musculoskeletal and connective tissue disorders	—	—	—	—
CEREBRAL MICROHAEMORRHAGE	Nervous system disorders	—	—	—	—
HYPERTENSION	Vascular disorders	—	—	—	—

Most-reported serious reactions: URINARY TRACT INFECTION, FALL, SYNCOPE, MYOCARDIAL INFARCTION, DIVERTICULITIS, PNEUMONIA, RIB FRACTURE, HYPONATRAEMIA.

Data from ClinicalTrials.gov NCT02880956 adverse events section.

Sponsor's own description

This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tau-targeting therapies for Alzheimer disease.
Congdon EE, Sigurdsson EM. · · 2018 · cited 838× · PMID 29895964 · DOI 10.1038/s41582-018-0013-z
Roles of tau protein in health and disease.
Guo T, Noble W, Hanger DP. · · 2017 · cited 710× · PMID 28386764 · DOI 10.1007/s00401-017-1707-9
Current and Future Treatments in Alzheimer Disease: An Update.
Yiannopoulou KG, Papageorgiou SG. · · 2020 · cited 553× · PMID 32165850 · DOI 10.1177/1179573520907397
Alzheimer's disease drug development pipeline: 2019.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2019 · cited 485× · PMID 31334330 · DOI 10.1016/j.trci.2019.05.008
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.
Boland B, Yu WH, Corti O, Mollereau B, et al · · 2018 · cited 422× · PMID 30116051 · DOI 10.1038/nrd.2018.109
Alzheimer's disease drug development pipeline: 2018.
Cummings J, Lee G, Ritter A, Zhong K. · · 2018 · cited 402× · PMID 29955663 · DOI 10.1016/j.trci.2018.03.009
Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options.
Cummings JL, Tong G, Ballard C. · · 2019 · cited 371× · PMID 30689575 · DOI 10.3233/jad-180766
Alzheimer's disease drug development pipeline: 2020.
Cummings J, Lee G, Ritter A, Sabbagh M, et al · · 2020 · cited 350× · PMID 32695874 · DOI 10.1002/trc2.12050

Verify or expand the search:

Other trials of ABBV-8E12

Trials testing the same drug.

NCT03413319 — Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 · Phase 1 · completed
NCT03391765 — An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) · Phase 2 · terminated
NCT02985879 — A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranu · Phase 2 · terminated
NCT03744546 — Expanded Access to ABBV-8E12 · no longer available

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting

Other AbbVie trials

Trials by the same sponsor.

NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02880956 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AbbVie
Last refreshed: 26 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02880956.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02880956

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (95 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of ABBV-8E12

Other recruiting trials for Alzheimer's Disease

Other AbbVie trials

Verify against primary sources